gutflix
GI learning, personalised

Summary

THE EFFICACY AND SAFETY OF VONOPRAZAN IN DUAL/ TRIPLE/QUADRUPLE REGIMENS BOTH IN FIRST-LINE AND RESCUE THERAPY FOR HELICOBACTER PYLORI ERADICATION: A SYSTEMATIC REVIEW WITH META-ANALYSIS

Javier P. Gisbert

UEG Week Copenhagen 2023 | Poster

Stomach & H. Pylori

October 15, 2023

A systematic review and meta-analysis of 75 studies found vonoprazan-based regimens achieved over 85% Helicobacter pylori eradication rates and outperformed proton pump inhibitors in first-line treatment and clarithromycin-resistant cases.

KEY POINTS

- Vonoprazan achieved 88% overall eradication rate across 44,992 patients, with similar tolerability to proton pump inhibitors (18% adverse event incidence).
- In treatment-naïve patients, vonoprazan significantly outperformed proton pump inhibitors (87% versus 70% eradication, risk difference 0.12, P<0.00001).
- Among clarithromycin-resistant strains, vonoprazan showed marked superiority over proton pump inhibitors (75% versus 39% eradication, risk difference 0.35, P<0.00001).
- No significant differences were found between vonoprazan and proton pump inhibitors in rescue therapy or in clarithromycin-susceptible patients, and dual versus triple vonoprazan regimens showed comparable efficacy in direct comparisons.
- This meta-analysis is most relevant for gastroenterologists managing Helicobacter pylori infection, particularly in regions with high clarithromycin resistance or in treatment-naïve patients.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/ed5302b8-743b-11ee-b9c9-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.